Ask AI
ProCE Banner Activity

Implementing Guidance Into Practice: Strategies for Carbapenem-Resistant Acinetobacter

Clinical Thought

Carbapenem-resistant Acinetobacter is a major cause of hospital-acquired and ventilator-acquired pneumonia. With evolving guidance around available antimicrobial agents, healthcare professionals have more tools at their disposal, but also more decisions to navigate. Read on to learn more about recent treatment advances, practical combination strategies, and how current recommendations translate to real-world care.

Released: December 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Innoviva Specialty Therapeutics, Inc.

Innoviva Specialty Therapeutics, Inc

Target Audience

This activity is intended for clinical specialists, including physicians and clinical pharmacists, and other healthcare professionals who design therapeutic regimens for patients with Acinetobacter baumannii-calcoaceticus complex infections.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Update strategies for timely identification of ABC infections that are not adequately covered by empiric therapy.

  • Select antibiotics to optimize safety and efficacy in the treatment of HAP and VAP caused by CRAB with diverse resistance mechanisms.

  • Design evidence-based antibiotic regimens for complex patients with ABC infections.